Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after β-blocker therapy

Circ Heart Fail. 2014 May;7(3):434-9. doi: 10.1161/CIRCHEARTFAILURE.113.000813. Epub 2014 Feb 21.

Abstract

Background: Some patients with left ventricular systolic dysfunction (LVSD) have a dramatic improvement in left ventricular ejection fraction (LVEF) after β-blockade. No study has analyzed the long-term echocardiographic and clinical follow-up of this subgroup of patients.

Methods and results: We included in this analysis 174 consecutive patients with LVSD who had an LVEF≥45% after β-blockade. We performed a long-term echocardiographic follow-up (median 7.7 [4-9.9] years) and clinical follow-up (median 9.2 [7.2-10.8] years). LVEF improved from 33±8% to 54±6% after β-blockade (P<0.0001). At the last echocardiographic evaluation, 26% of the patients had an LVEF<45% (mean±SD: 34±6%), whereas 74% still had an LVEF≥45% (mean±SD: 54±6%). Independent predictors of LVEF deterioration were a low LVEF, a high left ventricular end-diastolic diameter and a low heart rate after β-blockade, and the presence of a complete left bundle-branch block. In the overall study population, survival rates were 90% at 5 years and 75% at 10 years. Cardiovascular death rate was 9%, noncardiovascular death rate was 11%, and unknown death rate was 3%. Patients with subsequent LVEF deterioration had a higher cardiovascular mortality compared with patients with sustained recovered LVEF (22% versus 4%).

Conclusions: The long-term survival of patients with LVSD and with near-normal LVEF after β-blockade is good. However, a quarter of these patients may experience a subsequent degradation of LVEF. These patients are at higher risk of cardiovascular mortality.

Keywords: adrenergic beta-antagonists; heart failure, systolic; prognosis; ventricular dysfunction, left.

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology
  • Adrenergic beta-Antagonists / therapeutic use*
  • Adult
  • Aged
  • Comorbidity
  • Echocardiography
  • Female
  • Follow-Up Studies
  • Heart Failure / drug therapy*
  • Heart Failure / epidemiology
  • Heart Failure / physiopathology*
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prognosis
  • Risk Factors
  • Stroke Volume / drug effects
  • Stroke Volume / physiology*
  • Survival Rate
  • Systole / physiology
  • Time Factors
  • Treatment Outcome
  • Ventricular Dysfunction, Left / drug therapy*
  • Ventricular Dysfunction, Left / epidemiology
  • Ventricular Dysfunction, Left / physiopathology*

Substances

  • Adrenergic beta-Antagonists